Newsflash: Health Canada Brings Clarification

cb photo_98_4ee6a0b78e351Health Canada Brings Clarifications to the Data Protection Guidance Document
Catherine Lemay, December 2011

Health Canada recently announced that section 2.1 of its Guidance Document re: Data Protection has been amended to clarify that the prior approval of a medicinal ingredient in a drug for veterinary use will not preclude the granting of data protection for a drug for human use containing the identical medicinal ingredient or a variation thereof and vice versa.  Health Canada has not provided much rationale for its position other than its consistency with the policy intent underlying the 2006 amendments to the data protection provisions and the 1999 Federal Court of Appeal decision in Bayer Inc. v. Canada (Attorney General), 84 C.P.R. (3d) 129, aff’d 87 C.P.R. (3d) 293 which was rendered under the old data protection regime. 

For more information regarding data protection and other exclusivities in Canada, please do not hesitate to This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

Submit to DiggSubmit to FacebookSubmit to Google BookmarksSubmit to StumbleuponSubmit to TwitterSubmit to LinkedIn

cb photo 124 561ead1bced0d

DR. POONAM TAUH

Patent Agent


Poonam’s focuses on the drafting and prosecution of pharmaceutical, chemical, biochemical, petrochemical, and polymer patent applications around the world.
MBM read_more_btn

 

MBM logo

About MBM

 The process of invention is complete only with the IP protection provided in law. That's where MBM comes in. We match our clients' creative thinking with the creative protection needed to achieve their goals.Read More About MBM

EXPEDITING EXAMINATION IN CANADA - CHOOSING A PATH

There are currently three options available in Canada by which an Applicant can expedite issuance of a patent...Read More